Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Human Metabolome Technologies, Inc. ( (JP:6090) ).
Human Metabolome Technologies, Inc. reported a significant decline in its quarterly financial performance for September 2025, with net sales dropping by 29.8% compared to the previous year. The company also recorded negative operating and ordinary profits, indicating financial challenges that could impact its market position and stakeholder confidence.
The most recent analyst rating on (JP:6090) stock is a Hold with a Yen770.00 price target. To see the full list of analyst forecasts on Human Metabolome Technologies, Inc. stock, see the JP:6090 Stock Forecast page.
More about Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. operates in the biotechnology industry, focusing on metabolomics, which involves the comprehensive analysis of metabolites in biological samples. The company is listed on the Tokyo Growth stock exchange and is involved in general business activities.
Average Trading Volume: 8,039
Technical Sentiment Signal: Hold
Current Market Cap: Yen4.09B
See more insights into 6090 stock on TipRanks’ Stock Analysis page.